Latest Breaking News On - Institutional trading of eyepoint pharmaceuticals - Page 1 : comparemela.com

EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down to $11 16

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $11.16, but opened at $10.90. EyePoint Pharmaceuticals shares last traded at $11.13, with a volume of 79,034 shares. Analyst Ratings Changes Several research analysts have recently issued reports on the company. […]

Davidr guyerRobertw bairdInstitutional trading of eyepoint pharmaceuticalsSecurities exchange commissionEyepoint pharmaceuticals incEyepoint pharmaceuticals company profileMirae asset global investments coEyepoint pharmaceuticals stockNews ratings for eyepoint pharmaceuticals dailyDeutsche bankInvestment advisersEyepoint pharmaceuticalsTower research capitalAmeritas investment partners incGet free reportPoint pharmaceuticals

EyePoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by StockNews com

EyePoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by StockNews com
modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdJennison associatesInstitutional trading of eyepoint pharmaceuticalsFranklin resources incFirst turn managementEyepoint pharmaceuticals company profileEyepoint pharmaceuticals incSecurities exchange commissionHermes incEyepoint pharmaceuticalsAnalyst recommendations for eyepoint pharmaceuticalsEyepoint pharmaceuticals stockJpmorgan chase coNews ratings for eyepoint pharmaceuticals dailyGet free reportOne financial

EyePoint Pharmaceuticals (NASDAQ:EYPT) PT Lowered to $38 00

EyePoint Pharmaceuticals (NASDAQ:EYPT) PT Lowered to $38 00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdTower research capitalEyepoint pharmaceuticals tradingEyepoint pharmaceuticals incAnalyst recommendations for eyepoint pharmaceuticalsJpmorgan chase coInstitutional trading of eyepoint pharmaceuticalsEyepoint pharmaceuticalsToth financial advisory corpNews ratings for eyepoint pharmaceuticals dailySherbrooke park advisersChina universal asset management coInvestment advisersGet free reportCapital one financialPoint pharmaceuticals

Insider Selling: EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Insider Sells 49,325 Shares of Stock

Insider Selling: EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Insider Sells 49,325 Shares of Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Darioa paggiarinoNews ratings for eyepoint pharmaceuticals dailyLazard asset managementJpmorgan chase coQuarter for eyepoint pharmaceuticalsEyepoint pharmaceuticals incInstitutional trading of eyepoint pharmaceuticalsChina universal asset management coInvestment advisersToth financial advisory corpTower research capitalEyepoint pharmaceuticalsEyepoint pharmaceuticals tradingGet free reportPoint pharmaceuticalsOne financial

EyePoint Pharmaceuticals (NASDAQ:EYPT) Coverage Initiated by Analysts at JPMorgan Chase & Co

JPMorgan Chase & Co. began coverage on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research note published on Monday morning, Marketbeat.com reports. The firm issued an overweight rating and a $35.00 target price on the stock. A number of other research analysts have also recently issued reports on the company. Capital One […]

Darioa paggiarinoDekabank deutsche girozentraleWoodstock corpMirae asset global investments coSecurities exchange commissionEyepoint pharmaceuticals incAnalyst recommendations for eyepoint pharmaceuticalsJpmorgan chase coInstitutional trading of eyepoint pharmaceuticalsChina universal asset management coEyepoint pharmaceuticalsInvestment advisersNews ratings for eyepoint pharmaceuticals dailyEyepoint pharmaceuticals stock performanceFree reportOne financial